Core Insights - Huaxi Biological Technology (Tianjin) Co., Ltd. has been recognized as one of the first five "five-star" service capability units in the national list of biomanufacturing pilot platforms, showcasing its leading position in the biomanufacturing sector [1][2] - The pilot platform evaluation is part of the implementation of the "Implementation Opinions on the Innovative Development of Manufacturing Pilot" and focuses on three major tracks and nine key areas, aiming to accelerate the commercialization of scientific research achievements [1][2] - The platform has already served over 20 external companies and completed more than 30 projects transitioning scientific achievements to industrial applications, thus shortening the marketization cycle of innovative products [2] Group 1 - The pilot platform has met stringent standards in technology equipment, public infrastructure, service capability, and intellectual property protection, reflecting the company's technological accumulation and innovation capacity in biomanufacturing [2] - The company has established a complete innovation chain from basic research to industrial application, supported by a "research-development-pilot-industrialization" system that ensures efficient conversion of bioactive substances [2] - The platform is equipped with world-class fermentation systems, purification equipment, and testing instruments, with 64 flexible pilot production lines capable of large-scale conversion of six categories of bioactive substances [2] Group 2 - Looking ahead, the company aims to leverage its national-level platform to collaborate with upstream and downstream partners in the industry, providing comprehensive solutions and fostering a biotechnological innovation ecosystem [3] - The company plans to increase R&D investment, enhance pilot conversion efficiency, and accelerate the industrialization of biotechnological achievements, contributing to high-quality industry development [3] - The establishment of an industrialization ecological alliance is intended to create a cluster effect, promoting collaborative industry cooperation and advancing biomanufacturing into the 5.0 era [3]

Core Viewpoint - The company has established a subsidiary, Tuoxin Pharmaceutical (Sanya) Co., Ltd., in Hainan Free Trade Port, focusing on the research, production, and sales of pharmaceuticals, health products, and bioactive substances [1] Group 1 - The subsidiary is primarily engaged in the research and development of related products [1] - The company has already commenced some related business activities [1]